BNP Paribas Financial Markets Sells 16,880 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

BNP Paribas Financial Markets lowered its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 44.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,845 shares of the medical equipment provider’s stock after selling 16,880 shares during the quarter. BNP Paribas Financial Markets’ holdings in BioLife Solutions were worth $522,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC lifted its position in BioLife Solutions by 470.6% in the 3rd quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock valued at $333,000 after acquiring an additional 10,983 shares in the last quarter. D.A. Davidson & CO. acquired a new stake in shares of BioLife Solutions in the 3rd quarter valued at about $1,018,000. The Manufacturers Life Insurance Company raised its stake in shares of BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after purchasing an additional 5,638 shares during the period. Alpha DNA Investment Management LLC bought a new stake in shares of BioLife Solutions in the third quarter valued at about $467,000. Finally, Cerity Partners LLC boosted its position in shares of BioLife Solutions by 6.6% during the third quarter. Cerity Partners LLC now owns 44,914 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 2,776 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

BLFS has been the topic of a number of recent research reports. HC Wainwright dropped their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. TD Cowen lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Craig Hallum increased their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, KeyCorp raised their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and an average price target of $28.29.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $26.70 on Friday. The stock has a market capitalization of $1.24 billion, a PE ratio of -25.19 and a beta of 1.91. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a fifty day simple moving average of $24.62 and a 200 day simple moving average of $23.55. BioLife Solutions, Inc. has a 1-year low of $13.99 and a 1-year high of $28.88.

Insider Transactions at BioLife Solutions

In other news, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,593,412.40. The trade was a 3.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares in the company, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,313 shares of company stock worth $1,572,899 in the last ninety days. Insiders own 2.20% of the company’s stock.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.